Vaccinex Historical Income Statement

VCNX Stock

USD 3.62 0.02 0.56%

Historical analysis of Vaccinex income statement accounts such as Tax Provision of 0.0, Interest Income of 19.7 K, Depreciation And Amortization of 181 K or Interest Expense of 950 can show how well Vaccinex performed in making a profits. Evaluating Vaccinex income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Vaccinex's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Vaccinex latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Vaccinex is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaccinex. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Vaccinex Stock please use our How to Invest in Vaccinex guide.

About Vaccinex Income Statement Analysis

Vaccinex Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Vaccinex shareholders. The income statement also shows Vaccinex investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Vaccinex Income Statement Chart

At this time, Vaccinex's Depreciation And Amortization is fairly stable compared to the past year. Cost Of Revenue is likely to rise to about 17.4 M in 2024, whereas Net Interest Income is likely to drop (1.1 K) in 2024.

Interest Income Selling General Administrative Total Revenue Gross Profit Other Operating Expenses Research Development

Interest Income

Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.

Total Revenue

Total revenue comprises all receipts Vaccinex generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Vaccinex minus its cost of goods sold. It is profit before Vaccinex operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Vaccinex. It is also known as Vaccinex overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Vaccinex's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Vaccinex current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaccinex. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Vaccinex Stock please use our How to Invest in Vaccinex guide.At this time, Vaccinex's Depreciation And Amortization is fairly stable compared to the past year. Cost Of Revenue is likely to rise to about 17.4 M in 2024, whereas Net Interest Income is likely to drop (1.1 K) in 2024.

	2023	2024 (projected)
Depreciation And Amortization	119K	181K
Interest Income	20.7K	19.7K

Depreciation And Amortization Interest Income

Vaccinex income statement Correlations

	Net Interest Income	Interest Income	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Minority Interest	Reconciled Depreciation	Selling And Marketing Expenses
Net Interest Income		-0.99	0.39	-1.0	0.83	0.27	-0.47	0.55	-0.66	-0.86	-0.5	0.42	-0.5	0.48	0.7	-0.83	-0.95	-0.83	-0.94	-0.12	0.01	-0.44
Interest Income	-0.99		-0.38	0.99	-0.83	-0.32	0.4	-0.58	0.67	0.88	0.52	-0.44	0.52	-0.41	-0.7	0.85	0.98	0.85	0.94	0.1	-0.04	0.38
Depreciation And Amortization	0.39	-0.38		-0.39	0.41	-0.11	0.33	0.82	-0.83	-0.69	-0.92	0.84	-0.91	-0.32	0.77	-0.73	-0.46	-0.73	-0.34	0.69	0.77	0.25
Interest Expense	-1.0	0.99	-0.39		-0.83	-0.27	0.47	-0.55	0.66	0.86	0.5	-0.42	0.5	-0.48	-0.7	0.83	0.95	0.83	0.94	0.12	-0.01	0.44
Selling General Administrative	0.83	-0.83	0.41	-0.83		0.14	-0.47	0.52	-0.62	-0.73	-0.46	0.36	-0.46	0.47	0.68	-0.69	-0.75	-0.7	-0.65	-0.15	0.13	-0.42
Total Revenue	0.27	-0.32	-0.11	-0.27	0.14		-0.22	0.3	-0.28	-0.33	-0.17	0.28	-0.17	0.25	0.33	-0.31	-0.31	-0.33	-0.36	-0.15	-0.46	-0.19
Gross Profit	-0.47	0.4	0.33	0.47	-0.47	-0.22		0.11	0.09	0.19	-0.19	0.2	-0.19	-1.0	-0.22	0.1	0.25	0.09	0.39	0.52	0.57	0.93
Other Operating Expenses	0.55	-0.58	0.82	-0.55	0.52	0.3	0.11		-0.95	-0.87	-0.96	0.98	-0.96	-0.11	0.88	-0.9	-0.64	-0.9	-0.58	0.66	0.55	0.17
Operating Income	-0.66	0.67	-0.83	0.66	-0.62	-0.28	0.09	-0.95		0.93	0.96	-0.93	0.96	-0.1	-0.98	0.94	0.71	0.93	0.67	-0.57	-0.51	0.1
Net Income From Continuing Ops	-0.86	0.88	-0.69	0.86	-0.73	-0.33	0.19	-0.87	0.93		0.85	-0.8	0.86	-0.21	-0.93	1.0	0.91	0.99	0.88	-0.35	-0.37	0.19
Ebit	-0.5	0.52	-0.92	0.5	-0.46	-0.17	-0.19	-0.96	0.96	0.85		-0.97	1.0	0.18	-0.9	0.88	0.6	0.88	0.54	-0.74	-0.69	-0.17
Research Development	0.42	-0.44	0.84	-0.42	0.36	0.28	0.2	0.98	-0.93	-0.8	-0.97		-0.97	-0.19	0.85	-0.84	-0.53	-0.83	-0.49	0.77	0.6	0.23
Ebitda	-0.5	0.52	-0.91	0.5	-0.46	-0.17	-0.19	-0.96	0.96	0.86	1.0	-0.97		0.17	-0.9	0.89	0.61	0.88	0.54	-0.74	-0.68	-0.16
Cost Of Revenue	0.48	-0.41	-0.32	-0.48	0.47	0.25	-1.0	-0.11	-0.1	-0.21	0.18	-0.19	0.17		0.24	-0.11	-0.26	-0.1	-0.4	-0.53	-0.57	-0.95
Total Operating Expenses	0.7	-0.7	0.77	-0.7	0.68	0.33	-0.22	0.88	-0.98	-0.93	-0.9	0.85	-0.9	0.24		-0.92	-0.72	-0.91	-0.68	0.45	0.41	-0.27
Income Before Tax	-0.83	0.85	-0.73	0.83	-0.69	-0.31	0.1	-0.9	0.94	1.0	0.88	-0.84	0.89	-0.11	-0.92		0.9	1.0	0.85	-0.41	-0.43	0.09
Total Other Income Expense Net	-0.95	0.98	-0.46	0.95	-0.75	-0.31	0.25	-0.64	0.71	0.91	0.6	-0.53	0.61	-0.26	-0.72	0.9		0.9	0.95	-0.04	-0.17	0.24
Net Income	-0.83	0.85	-0.73	0.83	-0.7	-0.33	0.09	-0.9	0.93	0.99	0.88	-0.83	0.88	-0.1	-0.91	1.0	0.9		0.84	-0.41	-0.43	0.09
Income Tax Expense	-0.94	0.94	-0.34	0.94	-0.65	-0.36	0.39	-0.58	0.67	0.88	0.54	-0.49	0.54	-0.4	-0.68	0.85	0.95	0.84		-0.03	-0.04	0.35
Minority Interest	-0.12	0.1	0.69	0.12	-0.15	-0.15	0.52	0.66	-0.57	-0.35	-0.74	0.77	-0.74	-0.53	0.45	-0.41	-0.04	-0.41	-0.03		0.82	0.51
Reconciled Depreciation	0.01	-0.04	0.77	-0.01	0.13	-0.46	0.57	0.55	-0.51	-0.37	-0.69	0.6	-0.68	-0.57	0.41	-0.43	-0.17	-0.43	-0.04	0.82		0.49
Selling And Marketing Expenses	-0.44	0.38	0.25	0.44	-0.42	-0.19	0.93	0.17	0.1	0.19	-0.17	0.23	-0.16	-0.95	-0.27	0.09	0.24	0.09	0.35	0.51	0.49

Click cells to compare fundamentals

Vaccinex Account Relationship Matchups

Vaccinex income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Net Interest Income	0.0	(489K)	(809K)	(2K)	(1K)	(1.1K)
Depreciation And Amortization	401K	307K	169K	207K	119K	181K
Interest Expense	0.0	489K	809K	2K	1K	950.0
Selling General Administrative	6.7M	7.4M	6.2M	6.2M	6.9M	6.5M
Total Revenue	523K	50K	900K	100K	570K	450.0K
Gross Profit	324K	48K	731K	(107K)	(16.0M)	(15.2M)
Other Operating Expenses	32.5M	28.4M	23.4M	20.0M	23.5M	19.8M
Operating Income	(32.0M)	(28.3M)	(22.5M)	(19.9M)	(22.9M)	(24.0M)
Net Income From Continuing Ops	(31.9M)	(28.9M)	(22.4M)	(19.8M)	(22.0M)	(23.1M)
Ebit	(32.0M)	(28.4M)	(21.6M)	(19.8M)	(19.9M)	(20.9M)
Research Development	25.7M	21.5M	17.2M	14.0M	16.6M	15.0M
Ebitda	(31.6M)	(28.1M)	(21.4M)	(19.6M)	(19.7M)	(20.7M)
Cost Of Revenue	199K	2K	169K	207K	16.6M	17.4M
Total Operating Expenses	32.3M	28.4M	23.4M	20.0M	23.5M	27.0M
Income Before Tax	(31.9M)	(28.9M)	(22.4M)	(19.8M)	(20.3M)	(21.3M)
Total Other Income Expense Net	152K	(520K)	110K	91K	2.6M	1.4M
Net Income Applicable To Common Shares	(29.5M)	(31.9M)	(28.9M)	(22.4M)	(20.1M)	(21.1M)
Net Income	(32.0M)	(29.3M)	(23.2M)	(19.7M)	(20.3M)	(21.3M)
Income Tax Expense	152K	458K	852K	(93K)	(48.9K)	(46.5K)
Reconciled Depreciation	249K	307K	169K	207K	137K	171.2K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Vaccinex Stock Analysis

When running Vaccinex's price analysis, check to measure Vaccinex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaccinex is operating at the current time. Most of Vaccinex's value examination focuses on studying past and present price action to predict the probability of Vaccinex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaccinex's price. Additionally, you may evaluate how the addition of Vaccinex to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Vaccinex Historical Income Statement

About Vaccinex Income Statement Analysis

Vaccinex Income Statement Chart

Interest Income

Total Revenue

Gross Profit

Other Operating Expenses

Vaccinex income statement Correlations

Vaccinex Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Vaccinex income statement Accounts

Also Currently Popular

Additional Tools for Vaccinex Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Tax Provision	Net Interest Income
Interest Income	Depreciation And Amortization
Interest Expense	Selling General Administrative
Total Revenue	Gross Profit
Other Operating Expenses	Operating Income
Net Income From Continuing Ops	Ebit
Research Development	Ebitda
Cost Of Revenue	Total Operating Expenses
Income Before Tax	Total Other Income Expense Net
Net Income Applicable To Common Shares	Net Income
Income Tax Expense	Minority Interest
Reconciled Depreciation	Selling And Marketing Expenses

Income Before Tax	+ 1.0	Net Income From Continuing Ops
Ebitda	+ 1.0	Ebit
Net Income	+ 1.0	Income Before Tax
Interest Expense	+ 0.99	Interest Income
Net Income	+ 0.99	Net Income From Continuing Ops
Total Other Income Expense Net	+ 0.98	Interest Income

Cost Of Revenue	- 1.0	Gross Profit
Interest Expense	- 1.0	Net Interest Income
Interest Income	- 0.99	Net Interest Income
Total Operating Expenses	- 0.98	Operating Income
Ebitda	- 0.97	Research Development
Research Development	- 0.97	Ebit